10-Q: Masimo Q1 2026 Financial Results and Merger Update

Masimo Corporation reports Q1 2026 revenue of $403.6 million and continues progress toward its pending acquisition by Danaher Corporation.

Summary

• Total revenue for the first quarter of 2026 was $403.6 million, an 8.5% increase compared to $372.0 million in the same period of 2025.
• Net income from continuing operations was $56.3 million, compared to $47.2 million in the prior year period.
• Operating income was $77.4 million, slightly down from $78.0 million in the first quarter of 2025.
• The company incurred $17.9 million in expenses related to the pending merger with Danaher Corporation.
• As of April 4, 2026, the company had $124.6 million in cash and cash equivalents and $539.6 million in available borrowing capacity.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive report; while the core business shows growth, the company is heavily focused on the pending merger and managing significant legal and regulatory distractions.

Positives

• Revenue growth of 8.5% year-over-year, driven by increased consumables and service revenue.
• Net income from continuing operations improved to $56.3 million from $47.2 million.
• Successful completion of the sale of the non-healthcare consumer audio business (Sound United) in 2025, allowing focus on the core healthcare segment.
• Strong liquidity position with $539.6 million in available borrowing capacity under the current credit facility.

Negatives

• Operating income decreased slightly to $77.4 million from $78.0 million.
• Gross profit margin declined to 62.1% from 62.9%, primarily due to $6.7 million in incremental tariff expenses.
• Significant one-time costs of $17.9 million incurred during the quarter related to the pending merger.
• Ongoing legal and regulatory expenses related to multiple litigations, including disputes with Apple and former CEO Joe Kiani.

Risks

• Uncertainty regarding the timing and regulatory approval of the pending merger with Danaher Corporation.
• Potential for material financial impact from ongoing litigation with Apple and former CEO Joe Kiani.
• Exposure to tariff costs and supply chain volatility, which could continue to impact gross margins.
• Geopolitical instability in regions where the company operates, potentially disrupting business.
• Potential for further government investigations or subpoenas following the 2024 recall of Rad-G products.

Future Outlook

The company is focused on completing the pending merger with Danaher Corporation in 2026, subject to customary closing conditions and regulatory approvals. Management continues to prioritize the healthcare segment and expects to incur additional professional fees related to the merger.

Management Comments

• Management remains optimistic about long-term growth prospects in patient care and hospital automation.
• The company is actively working to mitigate tariff impacts through supply chain adjustments and administrative efforts.
• Management believes the company has strong defenses against ongoing litigation claims.

Industry Context

StockSavvy.ai notes that Masimo is navigating a transition period characterized by a strategic shift toward pure-play medical technology following the divestiture of its consumer audio business, while simultaneously preparing for acquisition by a major industry player, Danaher.

Comparison to Industry Standards

• Masimo's gross margin of 62.1% remains competitive within the medical device sector, though it faces pressure from tariff-related costs.
• The company's focus on hospital automation and connectivity aligns with broader industry trends toward digital health and interoperability, similar to strategies pursued by competitors like GE Healthcare and Philips.

Corporate Governance

Legal Proceedings

• Ongoing patent and trade secret litigation with Apple Inc.
• Securities class action settlement in principle reached in 2025.
• Derivative actions filed by stockholders regarding fiduciary duties.
• Litigation with former CEO Joe Kiani regarding employment agreement and severance.
• Arbitration with Willow Laboratories regarding cross-licensing agreement.

Related Party Transactions

• Cross-licensing agreement with Willow Laboratories, Inc., involving royalty payments.
• Sales to Cardinal Health, Inc., where Chairman Michelle Brennan serves as a director.

Stakeholder Impact

• Shareholders are expected to receive $180.00 per share in cash upon the completion of the merger with Danaher.
• Employees and customers may experience operational changes as the company integrates into Danaher.

Next Steps

• Complete the merger with Danaher Corporation in 2026.
• Continue to defend against ongoing litigation, including the Apple patent disputes and claims by former CEO Joe Kiani.
• Continue to monitor and respond to government subpoenas and investigations.

Key Dates

Recommendation

Given the pending merger with Danaher at a fixed cash price of $180.00 per share, the stock is expected to trade near this value, making it a hold for investors awaiting the deal's completion.

Keywords

Masimo, Medical Technology, Patient Monitoring, Danaher Merger, Pulse Oximetry, Healthcare Automation, SEC Filing